Today,
Gedeon Richter BioTech is evolving into a recognized European biotech player
with strong therapeutic focus in rheumatology, immunology, and osteoporosis.
The business develops and supplies safe, effective biosimilars and maintains a
sustainable pipeline shaped around the real needs of patients and prescribers.
Its
comprehensive capabilities, from R&D and analytics to mammalian and
microbial manufacturing and final drug product preparation, ensure reliability,
flexibility, and consistency at every step of the value chain.
As
healthcare systems around the world face rising demand for biologics and
increasing supply challenges, Richter’s European development and manufacturing
network provides resilience, security, and high scientific standards. GMP
approved, state-of-the-art facilities in Budapest and Debrecen in Hungary,
complemented by long-standing operations in Germany, form a robust
technological base supported by international regulatory approvals, strategic
collaborations with global partners and with the expertise of more than 1,000
biotech professionals.
With a
commitment to affordability, quality, and patient-centric solutions, Gedeon
Richter BioTech enables earlier access to advanced therapies, helps improve
quality of life, and supports sustainable healthcare budgets. Its dedication to
environmental responsibility, aligned with Europe’s ambitious climate goals,
reinforces a broader mission to deliver long-term value beyond cost savings
alone.
Trusted
science. Accessible care.
Biosimilars
do not have any significant differences from the reference medicine in terms of
quality, safety or efficacy. By competing with original biologics across a growing
range of therapy areas, biosimilars enable stakeholders, including payers,
physicians and patients, to benefit from greater choice when it comes to
treatment options.
Our focus in rheumatology reflects a commitment to improving the lives of millions of people living with chronic inflammatory diseases. These conditions can cause persistent pain, fatigue, and progressive joint damage, often affecting daily functioning and independence.
Advances in biotechnology enable targeted therapies that slow down disease progression and provide meaningful, lasting relief. By supporting earlier and more precise intervention, we aim to help healthcare professionals manage disease more effectively and support patients in preserving mobility, independence, and long-term quality of life.
We have a dedicated focus in supporting healthcare professionals and patients living with a range of autoimmune diseases. These complex conditions disrupt daily life through unpredictable and long-lasting symptoms and patients urgently need effective and accessible treatment options that address the underlying immune imbalance.
Drawing on biotechnology expertise, modern therapies act in a controlled and targeted way. By expanding access to these treatments, we aim to support healthcare professionals to better manage disease activity and transform these conditions into more predictable, manageable diseases.
Osteoporosis is a widespread condition that gradually weakens bones and increases the risk of fractures, affecting millions of people worldwide. As bone loss often develops silently, patients may remain undiagnosed until a serious fracture occurs.
Advances in biotechnology have expanded the therapeutic landscape, offering targeted treatment options that either reduce bone resorption or stimulate new bone formation. When used appropriately in patients at increased fracture risk, these therapies can contribute to improved skeletal outcomes and support the preservation of mobility and independence.
Our Budapest R&D pilot plant and associated laboratories represent a cornerstone of Gedeon Richter’s investment in biologics based on mammalian cell expression. The site was established specifically to enable the development of complex biological drug substances and products, supported by a comprehensive analytical infrastructure.
Designed to support early and advanced development activities, the Budapest facility enables the translation of scientific concepts into well characterised, robust production processes. Development work carried out here focuses on ensuring process consistency, product quality, and readiness for scale up, providing a strong technical foundation for downstream manufacturing.
As Richter’s central biologics development hub, the Budapest site plays a critical role in bridging research and industrial production, ensuring that innovation is built on scalable and manufacturable technologies.
Located in Debrecen’s industrial park, Gedeon Richter’s biologics manufacturing site provides commercial scale production capacity for biological drugs derived from mammalian cell fermentation. The facility was purpose built to support industrial manufacturing under GMP conditions, enabling reliable and reproducible supply for patients worldwide.
The Debrecen site integrates drug substance manufacturing with drug product fill & finish capabilities and all supporting services, ensuring high standards of quality and operational control across the production lifecycle. Its infrastructure is designed to support long term manufacturing programs, reflecting Richter’s strategic commitment to biologics as a core growth area.
Together, the Budapest development hub and the Debrecen manufacturing site form a fully integrated, end-to-end biologics ecosystem, enabling the efficient transfer of processes from development through to commercial production.
Richter BioLogics, the microbial biologics affiliate of Gedeon Richter, brings three decades of experience in the development and manufacture of products derived from bacterial and yeast expression systems. Operating GMP compliant sites in Northern Germany, the company produces recombinant proteins and peptides, plasmid DNA, and bacterial vaccines.
A team of close to 400 experts support Richter Biotech and third-party partners across the full value chain, from process and analytical development through clinical supply and commercial manufacturing, complemented by in house quality control and Qualified Person (QP) release.
In 2024, Richter BioLogics inaugurated a new, cutting edge biopharmaceutical cGMP facility in Bovenau, further strengthening its capacity for clinical and commercial production. This investment underscores Richter’s long term commitment to biologics manufacturing excellence and enhances the Group’s integrated European biologics platform.
To get to know more about our CDMO business, visit our dedicated website.